Oncobiologics (NASDAQ:OTLK) Director Ghiath Sukhtian Acquires 2,525,252 Shares

Oncobiologics, Inc. (NASDAQ:OTLK) Director Ghiath Sukhtian acquired 2,525,252 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was acquired at an average cost of $0.99 per share, with a total value of $2,499,999.48. Following the completion of the acquisition, the director owned 24,617,320 shares in the company, valued at $24,371,146.80. This trade represents a 11.43% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Oncobiologics Price Performance

Shares of OTLK stock opened at $0.76 on Friday. The company’s fifty day simple moving average is $1.31 and its two-hundred day simple moving average is $0.70. Oncobiologics, Inc. has a 1 year low of $0.16 and a 1 year high of $3.39. The stock has a market capitalization of $112.39 million, a price-to-earnings ratio of -0.65 and a beta of 0.82.

Oncobiologics (NASDAQ:OTLK) last posted its earnings results on Thursday, August 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.97 million. Equities research analysts anticipate that Oncobiologics, Inc. will post -0.49 EPS for the current year.

Analyst Upgrades and Downgrades

OTLK has been the subject of several analyst reports. Ascendiant Capital Markets raised their target price on Oncobiologics from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, June 11th. BTIG Research reiterated a “buy” rating and set a $4.00 price target on shares of Oncobiologics in a research report on Friday. Wall Street Zen downgraded shares of Oncobiologics from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings upgraded shares of Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. Finally, HC Wainwright raised their price objective on shares of Oncobiologics to $1.60 and gave the company a “neutral” rating in a research report on Monday, July 27th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $4.65.

Oncobiologics News Roundup

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and set a $4.00 price target, implying significant potential upside from recent trading levels. Benzinga analyst rating report
• Positive Sentiment: Management highlighted FDA approval of LYTENAVA, an ophthalmic bevacizumab product intended to address the U.S. wet age-related macular degeneration market. The approval could support future commercialization and revenue growth. Outlook Therapeutics third-quarter results and business update
• Positive Sentiment: Director Ghiath M. Sukhtian purchased 2.53 million shares for approximately $2.5 million, increasing his direct ownership by 11.43%. The insider purchase may be viewed as a vote of confidence in the company’s prospects. SEC insider transaction filing
• Neutral Sentiment: The company’s quarterly loss was $0.09 per share, compared with a $0.44 loss a year earlier, indicating year-over-year improvement but still missing the $0.08 consensus estimate. Zacks quarterly earnings report
• Negative Sentiment: Revenue was only approximately $10,000, far below the $970,000 consensus estimate. The revenue shortfall reinforces concerns about the timing of LYTENAVA’s commercial ramp and near-term cash generation. MarketBeat earnings report
• Negative Sentiment: Oncobiologics priced a $55 million public offering of 55.56 million shares at $0.99 each, along with immediately exercisable warrants carrying a $1.10 strike price. The large offering creates substantial dilution and likely contributed to selling pressure. Public offering announcement

Institutional Investors Weigh In On Oncobiologics

A number of institutional investors and hedge funds have recently made changes to their positions in OTLK. Russell Investments Group Ltd. boosted its stake in Oncobiologics by 865.2% during the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after buying an additional 21,941 shares during the period. AQR Capital Management LLC increased its stake in Oncobiologics by 42.7% in the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after acquiring an additional 25,351 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Oncobiologics by 74.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after acquiring an additional 44,063 shares during the last quarter. Hedge funds and other institutional investors own 11.20% of the company’s stock.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.